Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.62 |
| ▸ | GSK3B | P49841 | 5/20 | 0.62 |
| ▸ | PIM1 | P11309 | 4/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.51 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.50 |
| ▸ | CLK2 | P49760 | 4/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.50 |
| ▸ | GSK3A | P49840 | 3/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | PRKX | P51817 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636595 | 0.91 | ROCK2 (0.61) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3636127 | 0.87 | ROCK2 (0.61) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3670364 | 0.86 | ROCK2 (0.67) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3640238 | 0.86 | ROCK2 (0.59) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3671813 | 0.86 | ROCK2 (0.62) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3669367 | 0.84 | ROCK2 (0.65) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3668000 | 0.83 | ROCK2 (0.61) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3670618 | 0.83 | RAB9A (0.66) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3669674 | 0.82 | ROCK2 (0.56) | ROCK2GSK3BPIM1CLK4DYRK1A | |
| SCHEMBL3665457 | 0.81 | ROCK2 (0.58) | ROCK2GSK3BPIM1CLK4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090259041-A1 | QUINOLINE CARBOXYLIC ACID-O,O BIS-ACYLOXY BORATE AND PROCESS OF MAKING | SATYANARAYANA CHAVA | 2009-10-15 | — | — | US | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885PIM1 11/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885PIM1 11/4885 |
| US-20090259041-A1 | QUINOLINE CARBOXYLIC ACID-O,O BIS-ACYLOXY BORATE AND PROCESS OF MAKING | HAO1, DAO, HAO2 | ROCK2 4099/4885GSK3B 3993/4885PIM1 3150/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | ROCK2 858/4885GSK3B 1142/4885PIM1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.